Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors

NCT05010525 is registered in ClinicalTrials.gov with Shanghai Antengene Corporation Limited as lead sponsor.

NCT NCT05010525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05010525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Antengene Corporation Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
September 1, 2021
Completion date
November 14, 2022
Enrollment
8 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors